The Benjamin G. Neel Laboratory studies cell signaling, with a particular emphasis on protein-tyrosine phosphatases (PTPs). The roles of the SH2 domain-containing phosphatase Shp2 and its binding proteins in several human diseases are a major focus. We also have a interest in breast and ovarian cancer biology. The lab utilizes a wide array of technologies, including shRNA and CRISPR screens, cell biology, proteomics, flow cytometry, organoids, patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs).
Latest from the Neel Lab:
- Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy
- Congratulations to former Neel Lab grad student Shengqing Gu for his new job as Assistant Professor at MD Anderson!
- Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
- Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
- Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
- Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening
Keywords: SHP2, SHP1, PTP1B, PTPN11, PTPN1, PTPN6, RAS, ERK, RAF, MAPK, targeted therapies, immunotherapies, Rasopathies, Hypoxia, Moyamoya Disease, RNF213, ovarian cancer, breast cancer, HER2, organoids, mouse models, GEMMs.